GLP-1 Coverage Challenges and the CMS BALANCE Model in Obesity Treatment
Overview
Recent shifts in Medicaid coverage for GLP-1 medications highlight significant barriers to sustained obesity treatment. The CMS BALANCE model aims to improve access and adherence by negotiating standardized pricing and coverage, but its success depends on voluntary participation from state Medicaid programs and Medicare Part D plans.
Background
GLP-1 receptor agonists have become important pharmacologic options for obesity management, yet coverage by state Medicaid programs has been inconsistent, with four states dropping coverage since October 2025. The CMS BALANCE model, announced in December 2025, proposes a centralized negotiation of prices and coverage terms for GLP-1 and GLP-1/GIP receptor agonists to improve access for Medicare and Medicaid beneficiaries. Despite recognizing obesity as a disease, financial and structural barriers continue to drive medication discontinuation more than adverse effects. The model includes a bridge program offering a $50 monthly co-pay for Part D beneficiaries starting July 2026.
Data Highlights
As of October 2025, 16 state Medicaid programs covered GLP-1 medications for obesity; since then, 4 states have dropped coverage entirely. The BALANCE model proposes a $50 monthly co-pay for Medicare Part D beneficiaries beginning July 2026. US Department of Veteran Affairs data indicate that removing financial barriers can improve adherence to levels seen in phase 3 trials.
Key Findings
- Obesity is increasingly recognized as a disease, shifting policy perspectives on treatment coverage.
- Discontinuation of GLP-1 medications is more often due to cost and insurance issues than adverse effects.
- The CMS BALANCE model aims to negotiate standardized pricing and coverage for GLP-1 and GLP-1/GIP receptor agonists across Medicare Part D and Medicaid.
- Participation by state Medicaid programs and Medicare Part D plans is voluntary and uncertain, posing a risk to the model's success.
- The model includes a short-term bridge program with a $50 monthly co-pay to improve access starting July 2026.
- Advocacy by clinicians and institutions is critical to encourage stakeholder participation and ensure patient benefit.
Clinical Implications
Clinicians should be aware of the evolving coverage landscape for GLP-1 medications in obesity treatment, particularly the potential impact of the CMS BALANCE model starting in 2026. Understanding the financial and structural barriers to adherence can help guide patient counseling and advocacy efforts. Engaging with institutional stakeholders to support participation in the BALANCE model may improve access and outcomes for Medicare and Medicaid patients.
Conclusion
The CMS BALANCE model represents a promising policy shift toward improved access to GLP-1 therapies for obesity, but its success depends on overcoming structural barriers through stakeholder participation and advocacy. Clinicians play a key role in supporting these efforts to ensure patients benefit from these advances.
Related Resources & Content
- Gasoyan & Rothberg 2026 -- CMS BALANCE Model and GLP-1 Coverage in Obesity
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
